Medifast (MED) Set to Post Quarterly Earnings on Monday

Medifast (NYSE:MED) is projected to announce its Q3 2026 results after the market closes on Monday, October 26th. Analysts expect Medifast to post earnings of ($0.35) per share and revenue of $71.30 million for the quarter. Medifast has set its FY 2026 guidance at -1.750–0.250 EPS and its Q3 2026 guidance at -0.650–0.150 EPS. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Monday, October 26, 2026 at 8:30 AM ET.

Medifast (NYSE:MED) last released its earnings results on Monday, August 3rd. The specialty retailer reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.37. The firm had revenue of $76.38 million for the quarter, compared to the consensus estimate of $72.70 million. Medifast had a negative return on equity of 6.69% and a negative net margin of 8.08%. On average, analysts expect Medifast to post ($1.04) EPS for the current fiscal year and ($0.47) EPS for the next fiscal year.

Medifast Stock Performance

Shares of NYSE MED opened at $11.87 on Friday. The firm has a market cap of $132.71 million, a PE ratio of -5.09 and a beta of 0.68. Medifast has a one year low of $9.22 and a one year high of $13.45. The firm has a fifty day moving average of $11.95 and a 200 day moving average of $11.54.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on MED. Weiss Ratings raised Medifast from a “sell (e+)” rating to a “sell (d)” rating in a report on Monday, August 17th. Zacks Research raised Medifast from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 13th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $12.00.

Insider Buying and Selling

In other Medifast news, Director Daniel R. Chard sold 9,544 shares of the firm’s stock in a transaction dated Tuesday, September 29th. The stock was sold at an average price of $11.73, for a total transaction of $111,951.12. Following the completion of the sale, the director directly owned 130,609 shares in the company, valued at approximately $1,532,043.57. This trade represents a 6.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Parsa Kiai bought 43,150 shares of the company’s stock in a transaction on Wednesday, August 26th. The stock was purchased at an average cost of $12.26 per share, for a total transaction of $529,019.00. Following the completion of the transaction, the director owned 707,492 shares in the company, valued at approximately $8,673,851.92. The trade was a 6.50% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders acquired 119,966 shares of company stock valued at $1,423,576 over the last 90 days. 3.70% of the stock is currently owned by insiders.

About Medifast

Medifast, Inc (NYSE: MED) is a health and wellness company that provides weight-management products, programs and support services. Its primary brand, OPTAVIA, offers meal-replacement products, including shakes, bars, soups and other portion-controlled foods, along with structured plans intended to help customers establish healthier eating and lifestyle habits.

The company distributes its products primarily through an independent network of coaches who provide guidance, accountability and support to clients.